SCHEMBL5543992

SCHEMBL5543992

[CH2]c1nc(-c2ccc(F)cc2)oc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
ALDH1A1 P00352 3/20 0.43
ALOX15 P16050 1/20 0.43
TP53 P04637 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
TSHR P16473 2/20 0.42
HSD17B10 Q99714 1/20 0.42
POLB P06746 2/20 0.41
USP2 O75604 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MAPT P10636 3/20 0.40
NOTUM Q6P988 2/20 0.40
USP1 O94782 1/20 0.40
USP19 O94966 1/20 0.40
UCHL3 P15374 1/20 0.40
MAPK13 O15264 1/20 0.39
GCGR P47871 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5534898 0.81 TARBP2 (0.50) NPC1RAB9AALDH1A1ALOX15TP53
SCHEMBL5543997 0.81 NPC1 (0.52) NPC1RAB9AALDH1A1ALOX15TP53
SCHEMBL3758086 0.81 KDM4E (0.51) NPC1RAB9AALDH1A1SMN1; SMN2TSHR
SCHEMBL1868373 0.81 PTPN1 (0.51) NPC1RAB9AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL5543447 0.80 SLC9A1 (0.48) TP53KDM4ENOTUML3MBTL1GUSB
SCHEMBL1863083 0.79 TP53 (0.47) NPC1RAB9AALDH1A1TP53SMN1; SMN2
SCHEMBL1807664 0.76 NPC1 (0.36) NPC1RAB9AALDH1A1TP53SMN1; SMN2
SCHEMBL12961041 0.75 ALDH1A1 (0.52) NPC1RAB9AALDH1A1TP53TSHR
SCHEMBL5562436 0.75 RXFP1 (0.39) NPC1RAB9APOLBKDM4EMEN1
SCHEMBL5096428 0.74 ALDH1A1 (0.51) NPC1RAB9AALDH1A1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NPC1 2404/4885RAB9A 2824/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.